Skip to main content
Clinical Trials/NCT04592562
NCT04592562
Completed
Not Applicable

Genicular Artery Embolization to Reduce Pain Associated With Unilateral Mild to Moderate Osteoarthritis: A Pilot Study to Assess Feasibility

University of Chicago1 site in 1 country5 target enrollmentSeptember 22, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Knee Osteoarthritis
Sponsor
University of Chicago
Enrollment
5
Locations
1
Primary Endpoint
WOMAC Scale
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this study is to perform a feasibility study to show the effectiveness of the genicular artery embolization procedure in reducing bilateral or unilateral osteoarthritic knee pain at 12 months as measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score, Knee Injury and Osteoarthritis Outcome (KOOS) score, and Oswestry Disability Index.

Detailed Description

This is a single-center, pilot study to assess the feasibility of a study show the effectiveness of the genicular artery embolization (GAE) in reducing arthritic pain and dysfunction associated with mild to moderate Bilateral or unilateral osteoarthritis of the knee. Patients with bilateral or unilateral Grade 1-3 Osteoarthritis as diagnosed on standing weight-bearing knee radiographs per the Kellen-Lawrence Grading scale, will be offered enrollment to the study. Following a screening questionnaire, these patients will then be enrolled in this study. Baseline MRI will be obtained prior to the GAE procedure. Follow up intervals will include 3, 6, 9, and 12 months with the primary objective measured by a clinician as the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score, Knee Injury and Osteoarthritis Outcome (KOOS) score, and Oswestry Disability Index at the 12-month follow up visit. Patients will also undergo 1 year follow up MRI to be interpreted by a diagnostic radiologist with subspecialty training in musculoskeletal radiology. This radiologist will compare the treated knee to the baseline screening according to the WORMS classification (Whole Organ Magnetic Resonance Scoring) to assess for radiologic changes of osteoarthritis and any adverse effects.

Registry
clinicaltrials.gov
Start Date
September 22, 2021
End Date
May 28, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • We intend to include patients who meet the following criteria in the study:
  • Patients aged 40-80
  • Bilateral or Unilateral knee pain attributed to osteoarthritis
  • Grade 1-3 Osteoarthritis as diagnosed on standing weight-bearing knee radiographs per the Kellen-Lawrence Grading scale
  • Knee pain \>6 months refractory to conservative medical management (NSAIDs, paracetamol, intra-articular injections, physiotherapy/exercise, weight loss, etc.)

Exclusion Criteria

  • We plan to exclude patients who meet any of the following criteria:
  • Active malignancy
  • Active infection of the affected knee
  • Platelets \<50,000
  • INR \>1.8 (unless on anticoagulation that can be reversed)
  • Corticosteroid injection of the affected knee within 3 months
  • Rheumatoid arthritis or other seronegative arthropathy
  • Previous surgery (excluding arthroscopy) of the affected knee
  • Grade 4 per Kellgren-Lawrence Grading Scale of the affected knee
  • Pregnancy or expected pregnancy

Outcomes

Primary Outcomes

WOMAC Scale

Time Frame: 12 Months

The reduction of Bilateral or unilateral knee pain and dysfunction associated with mild to moderate osteoarthritis at 12 months as measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score

KOOS Scale

Time Frame: 12 Months

The reduction of Bilateral or unilateral knee pain and dysfunction associated with mild to moderate osteoarthritis at 12 months as measured by the Knee Injury and Osteoarthritis Outcome (KOOS) score

Oswestry Disability Index

Time Frame: 12 Months

The reduction of Bilateral or unilateral knee pain and dysfunction associated with mild to moderate osteoarthritis at 12 months as measured by the Oswestry Disability Index

Secondary Outcomes

  • WOMAC for Knee Pain and Dysfunction(12 Months)
  • KOOS for Knee Pain and Dysfunction(12 Months)
  • Oswestry Disability Index for Knee Pain and Dysfunction(12 Months)
  • Six-Minute Walk Test for Functional Improvement(12 months)
  • Thirty-Second Chair Test for Performance(12 Months)
  • VAS for Pain(12 Months)
  • Opiate Usage(12 Months)

Study Sites (1)

Loading locations...

Similar Trials